BLINCYTO ® (blinatumomab) Significantly Improved Overall Survival In Patients With B-Cell Precursor Acute Lymphoblastic Leukemia Compared To Chemotherapy

BLINCYTO Almost Doubled Median Overall Survival in High-Risk Patients With B-Cell Precursor Acute Lymphoblastic Leukemia Compared to Standard of Care Chemotherapy BLINCYTO is the First-and-Only Bispecific CD19-Directed CD3 T Cell Engager (BiTE®) Immunotherapy to Demonstrate Overall Survival Benefit in Patients With Philadelphia Chromosome-Negative Relapsed or Refractory Acute Lymphoblastic Leukemia Results Published in The New England Journal of Medicine THOUSAND OAKS, Calif., March 1, 2017 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the New England Journal of Medicine published results from the Phase 3 TOWER study evaluating the efficacy of BLINCYTO® (blinatumomab) versus s...
Source: Amgen News Release - Category: Pharmaceuticals Tags: Uncategorized Source Type: news